Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

    New ToleroMune(R) Treatment Extends Circassia's Clinical-Stage Portfolio

    OXFORD, England, May 13 /CNW/ - Circassia Ltd, a specialty
biopharmaceutical company focused on allergy, today announced that it has
initiated a phase II clinical development programme for its ragweed allergy
therapy. The treatment for allergic rhino-conjunctivitis caused by ragweed
pollen is based on Circassia's ToleroMune(R) technology, which has previously
achieved successful phase II results in patients with cat allergies. Ragweed
is one of the leading causes of allergic reactions in North America, where
allergies to its pollen are commonly referred to as 'hay fever'. Circassia is
undertaking its latest phase II clinical study in Canada. The double-blind,
randomised trial will include 50 patients with confirmed ragweed allergies,
and will compare a range of ToleroMune doses with placebo. Unlike most current
immunotherapies, which require careful dose escalation over many months and
several years of maintenance doses, patients will receive just four
standardized doses of ToleroMune treatment over a number of weeks. During the
trial investigators will 'challenge' the volunteers with ragweed pollen to
assess the impact of the therapy. "Broadening the range of allergies targeted
by ToleroMune is an important step for Circassia, underlining our confidence
in this breakthrough technology. We have already achieved encouraging results
in patients with cat allergies, and are excited to be extending our portfolio
of therapies to encompass ragweed allergy," said Steve Harris, Circassia's
CEO. "Allergies to ragweed pollen are very common in the US, where they affect
over a quarter of the population, and are a growing problem in Europe. We
believe that Circassia's new therapy should offer patients important benefits,
as ToleroMune has the potential to address the underlying cause of allergy
using short, simple courses of treatment that minimize the risk of severe and
sometimes life-threatening side effects associated with many existing

    About Circassia

    Circassia is a specialty biopharmaceutical company focused on the field
of allergy. The company's range of allergy therapeutics utilizes its
proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's
products offer potential major clinical benefits compared with existing
therapies, and consequently have significant market opportunities. Over 150
million people suffer from allergic rhinitis in the US and Europe, and the
current treatment market is approximately $12 billion per year. ToleroMune
technology has additional potential regulatory and supply benefits for
Circassia. Its state-of-the-art manufacturing fits with changes in the
European regulatory environment, where authorities are increasingly treating
allergen immunotherapies as pharmaceutical products, and eliminating the
batch-to-batch potency variability that is an intrinsic feature of many
currrent treatments. Circassia has a highly experienced management team with a
proven track record in product development and commercialization. Having
successfully completed two fundraising rounds the company is backed by a
syndicate of world-class venture capital and institutional investors,
including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco
    For more information please visit

For further information:

For further information: Steve Harris, Rob Budge, CEO RJB
Communications, Circassia, Tel: +44(0)1865-760969, Tel: +44(0)1865-784574

Organization Profile

Circassia Ltd

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890